Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
ADHD/Narcolepsy – Stimulants and Related Agents Applies to FFS and All MCOs as of 4/1/18; Wakix® and Sunosi™ as of 3/2/20; Qelbree™ as of 10/1/21: Azstarys™ as of 4/1/22		
Amphetamine Salt Combo – Adderall® Amphetamine Sulfate – Evekeo®	Attention Deficit Hyperactivity Disorders	F90.*
Dextroamphetamine / Amphetamine ER - Adderall XR® Dextroamphetamine Sulfate IR, ER - Dexedrine®, ProCentra®, Zenzedi®	Narcolepsy	G47.4*
A 1- 6''1 N' - '1®	Circadian Rhythm Sleep Disorder, Shift Work Type	G47.26
Armodafinil – Nuvigil [®] Modafinil – Provigil [®]	Narcolepsy	G47.4*
Wodarinii – Provigii	Obstructive Sleep Apnea	G47.33
Amphetamine ER − Adzenys XR–ODT TM , Dyanavel XR [®] Atomoxetine − Strattera [®] Lisdexamfetamine − Vyvanse [®] Methamphetamine − Desoxyn [®] Viloxazine − Qelbree TM Serdexmethylphenidate and Dexmethylphenidate − Azstarys [™]	Attention Deficit Hyperactivity Disorders	F90.*
Clonidine ER – Kapvay®	Attention Deficit Hyperactivity Disorders	F90.*
Guanfacine ER – Intuniv®	Tics / Tourette's Disorder	F95.*, G25.6*
Clonidine IR – Catapres®	Attention Deficit Hyperactivity Disorders	F90.*
Clonidine Patch – Catapres–TTS®	Hypertension	I10, I11.*, I12.*, I13.*, I15.*
Guanfacine IR – Tenex® Diagnosis only required if recipient is	Hypertension in Congenital Heart Disease	Q20.*, Q21.*, Q22.*, Q23.*, Q24.*, Q25.*, Q26.*, Q27.*, Q28.*
younger than 21 years of age	Tics / Tourette's Disorder	F95.*, G25.6*
Dexmethylphenidate – Focalin®	Cancer–Related Fatigue	R53.0
Dexmethylphenidate ER – Focalin XR®	Attention Deficit Hyperactivity Disorders	F90.*
Methylphenidate IR – Methylin [®] , Ritalin [®] Methylphenidate ER – Aptensio XR [®] , Concerta [®] , Metadate [®] CD/ER, QuilliChew ER [®] , Quillivant XR [®] ,	Cancer–Related Fatigue	R53.0
	Attention Deficit Hyperactivity Disorders	F90.*
Ritalin [®] LA/SR Methylphenidate Patch – Daytrana [®]	Narcolepsy	G47.4*
Pitolisant – Wakix®	Narcolepsy	G47.4*
Solriamfetol – Sunosi™	Narcolepsy	G47.4*
Somaniewi – Sunosi	Obstructive Sleep Apnea	G47.33

Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Antipsychotics Applies to FFS and All MCOs for Aripiprazole (Aristada® Initio®) and Risperidone (Perseris®) as of 1/9/19; All Other Antipsychotics as of 10/1/19; Secuado® as of 5/15/20;. Caplyta™ as of 8/3/2020; Invega Hafvera™ and Lybalvi™ as of 4/1/22		
Aripiprazole Oral – Abilify® Aripiprazole Injection Suspension – Abilify Maintena®	Agitation or Aggression or Irritability in Pervasive Developmental Disorder (PDD)/Autistic Disorder	
Aripiprazole Lauroxil ER Injection Suspension – Aristada®, Aristada® Initio™	† Negative Symptoms of PDD (Description is specific for olanzapine/fluoxetine)	F84.*
Asenapine – Saphris® Brexpiprazole – Rexulti®	Aggression or Irritability in PDD with Depression (Description is specific for perphenazine/amitriptyline)	
Cariprazine – Vraylar [®] Chlorpromazine Oral, Injection Clozapine – Clozaril [®] , FazaClo [®] , Versacloz [®]	Bipolar Disorder, Agitation or Psychoses in Bipolar Disorder, Agitation or Psychoses in Other Episodic Mood Disorders	
Fluphenazine Oral, Injection, Decanoate Injection Haloperidol Oral, Decanoate & Lactate Injection - Haldol [®] Iloperidone - Fanapt [®] , Fanapt [®] Titration Pack	† Bipolar Depression, Negative Symptoms of Psychoses in Bipolar Disorder, Negative Symptoms of Psychoses in Other Episodic Mood Disorders (Description is specific for olanzapine/fluoxetine)	F30.*, F31.*, F32.8*, F34.8*, F34.9, F39
Loxapine, Breath Activated Aerosol Powder – Adasuve® Loxapine Capsule Lurasidone – Latuda®	# Bipolar Disorder with Depression, Other Episodic Mood Disorders with Depression (Description is specific for perphenazine/amitriptyline)	
Lurasidone – Latuda® Olanzapine Oral and Injection – Zyprexa® Olanzapine Injection Suspension – Zyprexa Relprevv™ Paliperidone Oral – Invega® Paliperidone Injection <u>— Invega Hafyera®, Invega Sustenna®, Invega Trinza®</u> (1 month) — Invega Sustenna® Paliperidone Injection (3 month) — Invega Trinza® Perphenazine Prochlorperazine Oral and Injection – Compazine® Quetiapine – Seroquel® Quetiapine XR – Seroquel XR®	Delusions, Dementia, Psychoses or Agitation in Delusions, Dementia, Psychoses † Negative Symptoms of Delusions, Dementia or Psychoses (Description is specific for olanzapine/fluoxetine) ‡ Delusions with Depression, Dementia with Depression, Psychoses with Depression (Description is specific for perphenazine/amitriptyline)	F01.*, F02.*, F03.*, F04, F05, F06.0, F06.2, F06.30, F06.31, F06.32, F06.33, F06.34, F06.8, F10.150, F10.151, F10.250, F10.251, F10.26, F10.94, F10.950, F10.951, F10.96, F10.97, F11.121, F11.150, F11.151, F11.221, F11.250, F11.251, F11.251, F11.921, F11.950, F11.951, F12.121, F12.150, F12.151, F12.221, F12.250, F12.251, F12.921, F12.950, F12.951, F13.121, F13.150, F13.151, F13.221, F13.250, F13.251, F13.27, F13.921, F13.950, F13.951, F13.97, F14.121, F14.150, F14.151, F14.221, F14.250, F14.251, F14.921, F14.950, F14.951, F15.121, F15.150, F15.151, F15.221, F15.250, F15.251, F15.921, F15.950, F15.951, F16.121, F16.150, F16.151, F16.221, F16.250, F16.251, F16.921, F16.950, F16.951, F18.121, F18.150, F18.151, F18.17, F18.221, F18.250, F18.251, F18.27, F18.921, F18.950, F18.951, F18.97, F19.121, F19.150, F19.151, F19.17, F19.221, F19.250, F19.251, F19.27, F19.921, F19.950, F19.951, F19.97, F22, F23, F24, F28, F29, F32.3, F33.3, F44.89
Risperidone Oral – Risperdal® Risperidone Injection Suspension – Risperdal Consta®, Perseris™ Thioridazine Thiothixene Trifluoperazine Ziprasidone Oral and Injection – Geodon® Olanzapine/Fluoxetine – Symbyax®†	Schizophrenia or Schizoaffective Disorder or Agitation in Schizophrenia or Schizoaffective Disorder † Negative Symptoms of Schizophrenia or Schizoaffective Disorder (Description is specific for olanzapine/fluoxetine) ‡ Schizophrenia with Depression, Schizoaffective Disorder with Depression (Description is specific for perphenazine/amitriptyline)	F20.*, F25.*

Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Perphenazine/Amitriptyline#		
Antipsychotics Applies to FFS and All MCOs for A Caplyta™ as of 8/3/2020; Invega Hafyera™ and Lybalvi		/9/19; All Other Antipsychotics as of 10/1/19; Secuado® as of 5/15/20;.
Aripiprazole Oral – Abilify [®] Olanzapine Oral – Zyprexa [®] Quetiapine – Seroquel [®] Quetiapine XR – Seroquel XR [®]	Aggression in Conduct Disorder, Disruptive Behavior Disorder, Explosive Personality Disorder, Impulse Control Disorder, Intermittent Explosive Disorder, Isolated Explosive Disorder, Pervasive Developmental Disorder, or Unsocialized Aggression	F60.3, F63.3, F63.8*, F63.9, F84.*, F91.1, F91.8, F91.9
Risperidone Oral – Risperdal [®] Ziprasidone Oral – Geodon [®]	Additional Covered Codes: Borderline Personality Disorder, Depersonalization Disorder, Obsessive— Compulsive Disorder, Paranoid Personality Disorder	F42*, F48.1, F60.0, F60.3
Aripiprazole Oral – Abilify® Haloperidol Oral & Lactate Injection – Haldol® Pimozide – Orap® Quetiapine – Seroquel® Quetiapine XR – Seroquel XR® Risperidone Oral – Risperdal® Risperidone Injection Suspension – Risperdal Consta®	Tics/Tourette's Disorder	F95.*, G25.6*
·	Hiccough	R06.6
Chlorpromazine Oral, Injection	Nausea and Vomiting	G43.A0, K91.0, R11.*
Chiorpromazine Orai, injection	Porphyria	E80.0, E80.1, E80.20, E80.21, E80.29
	Tetanus	A35
Chlorpromazine Oral and Injection Haloperidol Oral – Haldol®	Attention Deficit Hyperactivity Disorder	F90.*
	Severe Behavioral Problems	F43.24, F63.81, F91.1, F91.8, F91.9
Perphenazine Prochlorperazine Oral, Injection and Rectal – Compazine®	Severe Nausea and Vomiting	G43.A0, K91.0, R11.*
Olanzapine/Fluoxetine — Symbyax® Perphenazine/Amitriptyline	Depression	F31.3*, F31.4, F31.5, F31.75, F31.76, F31.81, F31.9, F32.*, F33.*, F34.1

Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Perphenazine/Amitriptyline Prochlorperazine Oral – Compazine® Trifluoperazine	Anxiety	F06.4, F34.1, F41.*
Pimavanserin – Nuplazid™	Hallucinations and/or Delusions Associated with Parkinson's Disease Psychosis	G20
	Bipolar Disorder	F30.*, F31.*, F32.8*, F34.8*, F34.9, F39
Aripiprazole Tablet with Sensor – Abilify® Mycite®	Major Depressive Disorder	F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.9, F33*
1.10.11.1	Schizophrenia or Schizoaffective Disorder	F20.*, F25.*
Antipsychotics Applies to FFS and All MCOs for Caplyta™ as of 8/3/2020; Invega Hafyera™ and Lybalv.	Aripiprazole (Aristada® Initio®) and Risperidone (Perseris®) as of $1^{i^{1}}$ as of $4/1/22$	/9/19; All Other Antipsychotics as of 10/1/19; Secuado® as of 5/15/20;.
Asenapine Transdermal - Secuado® Lumateperone - Caplyta TM	Schizophrenia	F20.*
Brexpiprazole – Rexulti® Applies to FFS and All MCOs as of 7/1/21	Major Depressive Disorder	F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.9, F33*
Olanzapine and Samidorphan – Lybalvi™	Bipolar Disorder	F30.*, F31.*, F32.8*, F34.8*, F34.9, F39
Gianzapine and Sanndorphan - Lybarvi	Schizophrenia or Schizoaffective Disorder	<u>F20.*, F25.*</u>
Botulinum Toxins		
	Cervical Dystonia	G24.3
AbobotulinumtoxinA – Dysport®	ULS/LLS Associated with Complete Quadriplegia	G82.53
ULS – Upper Limb Spasticity	ULS/LLS Associated with Incomplete Quadriplegia	G82.54
ULS/LLS – Upper or Lower Limb Spasticity	ULS/LLS Associated with Cerebral Palsy	G80.0, G80.1, G80.2, G80.4, G80.8, G80.9
Applies to FFS and All MCOs as of 1/1/21	ULS Associated with Diplegia of Upper Limb	G83.0
	ULS/LLS Associated with Hemiplegia due to Late Effects of Cerebrovascular Disease	I69.•51, I69.•52, I69.•53, I69.•54, I69.•59
	ULS/LLS Associated with Intracranial Injury of Other and Unspecified Nature (Traumatic Brain Injury)	S06.1*, S06.2*, S06.3*, S06.4*, S06.5*, S06.6*, S06.8*, S06.9*

Louisiana	Medicaid – Medications Requiring IC	CD-10 Diagnosis Codes
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
	Spasticity Associated with Monoplegia of Upper or Lower Limb	G83.1*, G83.2*, G83.3*
	Spasticity Associated with Monoplegia of Upper or Lower Limb due to Late Effects of Cerebrovascular Disease	I69.•31, I69.•32, I69.•33, I69.•34, I69.•39, I69.•41, I69.•42, I69.•43, I69.•44, I69.•49
	ULS/LLS Associated with Multiple Sclerosis (Relapsing)	G35
	ULS/LLS Associated with Spastic Hemiplegia	G81.1*
	ULS/LLS Associated with Spinal Cord Injury without Evidence of Spinal Bone Injury	S14.0*, S14.1•5, S14.1•6, S14.1•7
Botulinum Toxins		
	Blepharospasm	G24.5
	Cervical Dystonia	G24.3
	Chronic Sialorrhea	K11.7
	ULS Associated with Multiple Sclerosis (Relapsing)	G35
IncobotulinumtoxinA – Xeomin®	ULS Associated with Cerebral Palsy	G80.0, G80.1, G80.2, G80.4, G80.8, G80.9
ULS – Upper Limb Spasticity ULS/LLS – Upper or Lower Limb Spasticity	ULS Associated with Spastic Hemiplegia	G81.1*
	ULS Associated with C5–C7 Complete Quadriplegia	G82.53
Applies to FFS and All MCOs as of 1/1/21	ULS Associated with C5–C7 Incomplete Quadriplegia	G82.54
	ULS Associated with Diplegia of Upper Limb	G83.0
	ULS Associated with Monoplegia of Upper Limb due to Late Effects of Cerebrovascular Disease	I69.•31, I69.•32, I69.•33, I69.•34, I69.•39
	ULS Associated with Hemiplegia due to Late Effects of Cerebrovascular Disease	I69.•51, I69.•52, I69.•53, I69.•54, I69.•59

Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
	ULS Associated with Intracranial Injury of Other and Unspecified Nature (Traumatic Brain Injury)	S06.1*, S06.2*, S06.3*, S06.4*, S06.5*, S06.6*, S06.8*, S06.9*
	ULS Associated with Monoplegia of Upper Limb	G83.2*
	ULS Associated with Spinal Cord Injury without Evidence of Spinal Bone Injury (C5–C7)	S14.0*, S14.1•5, S14.1•6, S14.1•7
Botulinum Toxins		
	Axillary Hyperhidrosis	L74.510
	Blepharospasm	G24.5
	Cervical Dystonia	G24.3
	Chronic Migraine (Prophylaxis)	G43.7*
	Overactive Bladder	N32.81
OnabotulinumtoxinA – Botox®	Strabismus	H49.*, H50.*, H51.*
	ULS/LLS Associated with Multiple Sclerosis (Relapsing)	G35
ULS – Upper Limb Spasticity ULS/LLS – Upper or Lower Limb Spasticity	ULS/LLS Associated with Cerebral Palsy	G80.0, G80.1, G80.2, G80.4, G80.8, G80.9
	ULS/LLS Associated with Spastic Hemiplegia	G81.1*
Applies to FFS and All MCOs as of 1/1/21	ULS/LLS Associated with Complete Quadriplegia	G82.53
	ULS/LLS Associated with Incomplete Quadriplegia	G82.54
	ULS Associated with Diplegia of Upper Limb	G83.0
	Spasticity Associated with Monoplegia of Upper or Lower Limb	G83.1*, G83.2*, G83.3*
	Spasticity Associated with Monoplegia of Upper or Lower Limb due to Late Effects of Cerebrovascular Disease	I69.•31, I69.•32, I69.•33, I69.•34, I69.•39, I69.•41, I69.•42, I69.•43, I69.•44, I69.•49

Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
•	ULS/LLS Associated with Hemiplegia due to Late Effects of Cerebrovascular Disease	I69.•51, I69.•52, I69.•53, I69.•54, I69.•59
	ULS/LLS Associated with Intracranial Injury of Other and Unspecified Nature (Traumatic Brain Injury)	S06.1*, S06.2*, S06.3*, S06.4*, S06.5*, S06.6*, S06.8*, S06.9*
	ULS/LLS Associated with Spinal Cord Injury without Evidence of Spinal Bone Injury	S14.0*, S14.1•5, S14.1•6, S14.1•7
	Urinary Incontinence (Detrusor Overactivity Associated with Neurological Disease)	N36.44, N31.9
Botulinum Toxins		
RimabotulinumtoxinB – Myobloc®	Cervical Dystonia	G24.3
Applies to FFS and All MCOs as of 1/1/21	Chronic Sialorrhea	K11.7
Pulmonary Arterial Hypertension (PAI	H)	
Ambrisentan – Letairis® Bosentan – Tracleer® Epoprostenol Sodium – Veletri®, Flolan® Iloprost – Ventavis® Macitentan – Opsumit® Riociguat – Adempas® Treprostinil – Orenitram®, Remodulin®, Tyvaso® Applies to FFS and All MCOs as of 1/1/21	Pulmonary Arterial Hypertension (PAH)	I27.0, I27.2*, I27.89, P29.3*
Tadalafil – Adcirca [®] Sildenafil – Revatio [®] Applies to FFS and All MCOs as of 6/1/18	Pulmonary Arterial Hypertension (PAH)	I27.0, I27.2*, I27.89, P29.3*

Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Tadalafil – Cialis® 2.5mg, 5mg	Benign Prostatic Hypertrophy (BPH)	N40.*
Erectile Dysfunction (ED) Applies to FFS	and All MCOs as of 6/1/18	
Avanafil – Stendra [®] Sildenafil – Viagra [®] Vardenafil – Levitra [®] , Staxyn [®]	No Acceptable Diagnosis Code	No Acceptable Diagnosis Code
Hepatitis C Applies to FFS and All MCOs a.	s of 5/9/18	
Elbasvir/Grazoprevir – Zepatier® Glecaprevir/Pibrentasvir – Mavyret® Ledipasvir/Sofosbuvir – Harvoni® Ombitasvir/Paritaprevir/Ritonavir & Dasabuvir – Viekira Pak® Peginterferon Alfa–2B – PegIntron® Ribavirin – Copegus®, Moderiba®, Rebetol®, Ribasphere® Sofosbuvir – Sovaldi® Sofosbuvir / Velpatasvir – Epclusa®	Chronic Hepatitis C	B18.2
Other Interferons Applies to FFS and All MCOs as of 4/7/21		
	AIDS-Related Kaposi's Sarcoma	C46.*
	Chronic Hepatitis B	B18.0, B18.1
	Chronic Hepatitis C	B18.2
Interferon Alfa–2B Recombinant – Intron A®	External Genital Warts (Condylomata Acuminata)	A63.0
	Follicular Lymphoma	C82.*
	Hairy Cell Leukemia	C91.4*

Louisiana Medicaid – Medications Requiring ICD–10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
	Melanoma	C43.*
	Chronic Granulomatous Disease	D71
Interferon Gamma–1B – Actimmune®	Malignant Osteopetrosis	Q78.2
Parintanfanan Alfa 2A Pagagya®	Chronic Hepatitis B	B18.0, B18.1
Peginterferon Alfa–2A – Pegasys®	Chronic Hepatitis C	B18.2
Peginterferon Alfa–2B – Sylatron®	Melanoma	C43.*
Hormones Applies to FFS and All MCOs a	as of 4/7/21	
Goserelin Acetate (1 month) –	Breast Cancer (Female)	C50.•1*
Zoladex® 3.6mg	Dysfunctional Uterine Bleeding	N89.7, N92.5, N93.8
	Endometriosis	N80.*
	Prostate Cancer	C61
Goserelin Acetate (3 month) – Zoladex® 10.8mg Histrelin Acetate – Vantas® Leuprolide Acetate – Eligard®, Lupron Depot® 7.5mg, 22.5mg (3 month), 30mg (4 month), 45mg (6 month) Triptorelin Pamoate – Trelstar®	Prostate Cancer	C61
Histrelin Acetate –Supprelin LA® Leuprolide Acetate – Lupron Depot–Ped®, Fensolvi® Triptorelin Pamoate – Triptodur®	Central Precocious Puberty	E30.1, E30.8
Leuprolide Acetate – Lupron®	Central Precocious Puberty	E30.1, E30.8
Daptoniae rectute Dapton	Prostate Cancer	C61
Leuprolide Acetate – Lupron Depot®	Endometriosis	N80.*
3.75mg, 11.25mg (3 month)	Uterine Leiomyoma	D25.*
Hydroxyprogesterone – Makena®, Generic, Authorized Generic	Pregnancy with History of Preterm-Labor	O09.21*
	Central Precocious Puberty	E30.1, E30.8

Louisiana Medicaid – Medications Requiring ICD–10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Nafarelin Acetate – Synarel®	Endometriosis	N80.*
Oral Contraceptives	Premenstrual Dysphoric Disorder	F32.81
Educational alert at Point-of-Sale Suggests a diagnosis code if one is not	Excessive and Frequent Menstruation	N92*
submitted on the pharmacy claim Applies to FFS and All MCOs as of 10/1/18	Encounter for Contraceptive Management	Z30*
Progesterone – Crinone® Applies to FFS and All MCOs as of 8/1/19	Secondary Amenorrhea	N91.1
Topical Applies to FFS and All MCOs as of 4	1/7/21	
Imiquimod – Zyclara® 2.5%	Actinic Keratosis	L57.0
Imiquimod – Zyclara® 3.75%	Actinic Keratosis	L57.0
	External Genital Warts (Condylomata Acuminata)	A63.0
	Actinic Keratosis	L57.0
Imiquimod – Aldara® 5%	External Genital Warts (Condylomata Acuminata)	A63.0
	Superficial Basal Cell Carcinoma	C44.•1*

Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Tazarotene – Tazorac® Diagnosis for psoriatic arthritis bypasses age limit that applies to acne agents Applies to FFS and All MCOs as of 7/1/19	Psoriatic Arthritis	L40.*
Doxepin – Prudoxin®, Zonalon®	Atopic Dermatitis	L20.*
Applies to FFS and All MCOs as of 5/15/20	Lichen Simplex Chronicus	L28.0
Triptans Diagnosis only required if recipient is younger than 18 years of age Applies to Tosymra® for FFS and All MCOs as of 12/16/19. Applies to all other Triptans for FFS and All MCOs as of 4/7/21		
Almotriptan – Axert® Eletriptan – Relpax® Frovatriptan – Frova® Naratriptan – Amerge® Rizatriptan – Maxalt®, Maxalt MLT® Sumatriptan [Oral, Nasal] – Imitrex®, Onzetra Xsail®, Tosymra® Sumatriptan [Injection] – Zembrace SymTouch® Zolmitriptan – Zomig®, Zomig ZMT®	Migraine	G43.0*, G43.1*, G43.7*
Sumatriptan [Injection] – Imitrex®, Sumavel®	Migraine	G43.0*, G43.1*, G43.7*
	Cluster Headache, Acute	G44.009
Substance Use Disorder (SUD)		

Applies to FFS and All MCOs as of 4/1/18. Sublocade® and Vivitrol® as of 9/4/18. Lucemyra® and Naltrexone Tablets as of 4/7/21.

Louisiana Medicaid – Medications Requiring ICD–10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Buprenorphine HCl – Subutex® Buprenorphine HCl / Naloxone HCl – Bunavail®, Suboxone®, Zubsolv® Buprenorphine Implant Kit – Probuphine® Buprenorphine Extended Release Injection – Sublocade®	Opioid Type Dependence	F11.2*
Naltrexone – Vivitrol®	Alcohol Dependence	F10.2*
Naltrexone Tablets	Opioid Type Dependence	F11.2*
Lofexidine – Lucemyra®	Opioid Abuse, Dependence or Use [Unspecified] With Withdrawal	F11.13, F11.23, F11.93
Miscellaneous		
Aldesleukin – Proleukin®	Melanoma	C43.*
Applies to FFS and All MCOs as of 1/1/21	Renal Cell Carcinoma	C64.*
Amikacin Inhalation Suspension – Arikayce® Applies to FFS and All MCOs as of 11/1/19	Mycobacterium avium complex	A31.0, A31.2
Tobramycin - Kitabis Pak® Applies to FFS and All MCOs as of 8/1/19	Cystic Fibrosis with Pseudomonas	E84.*
Aztreonam – Cayston® Tobramycin – Bethkis®, Tobi® Applies to FFS and All MCOs as of 1/1/21	Cystic Fibrosis with Pseudomonas	E84.*
Alprazolam ODT – Niravam®	Generalized Anxiety Disorder	F41.1
	Panic Disorder with Agoraphobia	F40.01
Applies to FFS and All MCOs as of 11/1/19	Panic Disorder without Agoraphobia	F41.0
Alprazolam XR – Xanax XR®	Panic Disorder with Agoraphobia	F40.01
Applies to FFS and All MCOs as of 11/1/19	Panic Disorder without Agoraphobia	F41.0
Fentanyl Buccal/Sublingual – Abstral [®] , Actiq [®] , Fentora [®] , Lazanda [®] , Subsys [®] Applies to FFS and All MCOs as of 1/1/21	Cancer	C00.*-C96.*

Louisiana Medicaid – Medications Requiring ICD–10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Deferiprone - Ferriprox® Applies to FFS and All MCOs as of 1/1/22 Deferasirox - Exjade®, Jadenu® (2 to 9 years of age) Brand Applies to FFS and All MCOs as of 8/3/20	Chronic Iron Overload Due to Blood Transfusions	E83.111
Generic Applies to FFS and All MCOs as of 10/7/20 Deferasirox – Exjade®, Jadenu® (10 years of age and older)	Chronic Iron Overload Due to Blood Transfusions	E83.111
Brand Applies to FFS and All MCOs as of 8/3/20 Generic Applies to FFS and All MCOs as of 10/7/20	Chronic Iron Overload Due to Non–Transfusion– Dependent Thalassemias	D56.0, D56.1, D56.5, D56.8, D57.4*
Dornase Alfa – Pulmozyme [®] Applies to FFS and All MCOs as of 1/1/21	Cystic Fibrosis	E84.*
Ivermectin (oral) – Stromectol® Applies to FFS and All MCOs as of 9/1/21	Unspecified Parasitic Disease	B89
Sacubitril / Valsartan – Entresto® Applies to FFS and All MCOs as of 10/1/21	Heart Failure	I50*
Miscellaneous		
Paroxetine – Brisdelle® Applies to FFS and All MCOs as of 8/1/18	Moderate to Severe Vasomotor Symptoms Associated with Menopause	E28.310, E89.41, N95.1
	Hemolytic-Uremic Syndrome	D59.3
Eculizumab – Soliris® Applies to FFS and All MCOs as of 8/1/18	Paroxysmal Nocturnal Hemoglobinuria (Marchiafava–Micheli)	D59.5
	Myasthenia Gravis	G70.0
Applies to FFS and All MCOs as of 11/1/19	Neuromyelitis Optica Spectrum Disorder (NMOSD)	G36.0
Ravulizumab - Ultomiris®	Hemolytic-Uremic Syndrome	D59.3
Applies to FFS and All MCOs as of 8/3/20	Paroxysmal Nocturnal Hemoglobinuria (Marchiafava–Micheli)	D59.5
Agalsidase beta – Fabrazyme [®] Applies to FFS and All MCOs as of 11/1/19	Fabry (–Anderson) Disease	E75.21
Alglucosidase alfa – Lumizyme [®] Applies to FFS and All MCOs as of 11/1/19 Avalglucosidase alfa-ngpt – Nexviazyme TM Applies to FFS and All MCOs as of 1/1/22	Pompe Disease	E74.02
Methadone Applies to FFS and All MCOs as of 1/1/21	Diagnosis <i>must</i> be submitted, but <i>cannot</i> be Substance Use Disorder	Diagnosis <i>must</i> be submitted but <i>cannot</i> be F11.2*

Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Buprenorphine – Belbuca® Applies to FFS and All MCOs as of 1/1/21	Diagnosis <i>must</i> be submitted, but <i>cannot</i> be Substance Use Disorder	Diagnosis <i>must</i> be submitted but <i>cannot</i> be F11.2*
Edaravone – Radicava® Riluzole – Rilutek®; Tiglutik™; Exservan™* Applies to FFS and All MCOs as of 3/2/20 & *1/1/22	Amyotrophic Lateral Sclerosis	G12.21
Inotersen – Tegsedi [®] Patisiran – Onpattro [®] Applies to FFS and All MCOs as of 3/2/20	Polyneuropathy of Hereditary Transthyretin– Mediated Amyloidosis	E85.1
Pomalidomide – Pomalyst® Applies to FFS and All MCOs as of 11/1/19	Multiple Myeloma	C90.0*
Quinine Sulfate 324mg – Qualaquin® Applies to FFS and All MCOs as of 8/3/20	Plasmodium falciparum malaria, unspecified	B50.9
Tiotropium Bromide – Spiriva® Respimat®	1.25 mcg – Asthma	J45*
Applies to FFS and All MCOs as of 10/7/20	2.5 mcg – COPD	J44*
Pegcetacoplan – Empaveli [™] Applies to FFS and All MCOs as of 4/1/22	Paroxysmal Nocturnal Hemoglobinuria (Marchiafava–Micheli)	<u>D59.5</u>
HIV Agents Applies to FFS and All MCOs a	s of 11/1/19	
	Acute hepatitis B with delta–agent without hepatic coma	B16.1
	Acute hepatitis B without delta–agent with hepatic coma	B16.2
	Acute hepatitis B without delta–agent and without hepatic coma	B16.9
*****	Chronic viral hepatitis B with delta–agent	B18.0
HIV Agents	Chronic viral hepatitis B without delta–agent	B18.1
(Except Descovy® and Truvada®)* *Exception applies to FFS and All MCOs as	Unspecified viral hepatitis B	B19.1
of 4/1/22	Unspecified viral hepatitis B without hepatic coma	B19.10
Applies to FFS and All MCOs as of 11/1/19	Unspecified viral hepatitis B with hepatic coma	B19.11
	Human immunodeficiency virus [HIV] disease	B20
	Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere	B97.35
	Contact with hypodermic needle	W46.0XXA, W46.0XXD
	Contact with contaminated hypodermic needle	W46.1XXA, W46.1XXD
	Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission	Z20.2

Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
	Contact with and (suspected) exposure to HIV	Z20.6
	Contact with and (suspected) exposure to other viral communicable diseases	Z20.828
	Contact with and (suspected) exposure to other communicable diseases	Z20.89
	Contact with and (suspected) exposure to unspecified communicable disease	Z20.9
	Carrier of viral hepatitis B	Z22.51
	High risk sexual behavior	Z72.5
	High risk heterosexual behavior	Z72.51
	High risk homosexual behavior	Z72.52
	High risk bisexual behavior	Z72.53
	Contact with and (suspected exposure to potentially hazardous body fluids	Z77.21
	Other contact with and (suspected) exposure hazardous to health	Z77.9
Risk Factors Required with Orlistat Re		ing Orlistat use. Applies to FFS and All MCOs as of 4/7/21
	Atherosclerosis	170.*
	Cerebrovascular Disease	I60.*, I61.*, I62.*, I63.*, I65.*, I66.*, I67.*, I68.*, I69.*
	Dyslipidemia	E78.0–E78.5
	Gastric Reflux Disease	K21.0, K21.9
	Hyperinsulinemia	E15, E16.1
0.11.4.4 V 1.18	Hypertension	I10, I11.*, I12.*, I13.*, I15.*
Orlistat – Xenical®	Impaired Glucose Tolerance	R73.02
	Ischemic Heart Disease	I21.*, I22.*, I24.*, I25.*
	Osteoarthritis of Hips/Knees	M16.*, M17.*
	Other Peripheral Vascular Diseases	173.*
	Phlebitis & Thrombophlebitis of Lower Extremities, unspecified	180.3
	Phlebitis & Thrombophlebitis of Other Deep Vessels	I80.2*

Louisiana Medicaid – Medications Requiring ICD–10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
	Phlebitis & Thrombophlebitis of the Femoral Vein	I80.1*
	Phlebitis & Thrombophlebitis of the Superficial Vessels of the Lower Extremities	I80.0*
	Pseudotumor Cerebri	G93.2
	Sleep Apnea	G47.30
	Type 2 Diabetes	E11.*
	Varicose Veins of Lower Extremities, with Inflammation	I83.1*
	Varicose Veins of Lower Extremities, without Mention of Ulcer and Inflammation	I83.9*
	Varicose Veins of Lower Extremities, with Ulcer	I83.0*
	Varicose Veins of the Lower Extremities with Ulcer and Inflammation	I83.2*
Histamine H ₂ Antagonists & Sucralfate	Applies to FFS and All MCOs as of 11/1/19	
	Abscess of Esophagus	K20.8
	Barrett's Esophagus	K22.7*
	Chronic Pancreatitis	K86.0, K86.1
	Crohn's Disease	K50.*
	Duodenal Ulcer	K26.*
imetidine – Tagamet®	Esophagitis, unspecified	K20.9
amotidine – Pepcid®	Gastric Hyperacidity	K30
izatidine – Axid®	Gastric Ulcer	K25.*
ucralfate – Carafate®	Gastritis / Duodenitis	K29.*
	Gastroesophageal Reflux Disease (GERD)	K21.9
Diagnosis codes submitted on the pharmacy	Gastrointestinal Hemorrhage	K92.2
laim will bypass the duration of therapy	Malignant Mast Cell Tumors	C96.2*
limit	Multiple Endocrine Adenomas	D44.0, D44.2, D44.9
	Peptic Ulcer	K27.*
	Reflux Esophagitis	K21.0
	Ulcer of Esophagus with OR without Bleeding	K22.1*
	Zollinger–Ellison Syndrome	E16.4
Proton Pump Inhibitors (PPIs) Applies to		120.1
Dexlansoprazole – Dexilant®	Abscess of Esophagus	K20.8
1	1 0	

Louisiana Medicaid – Medications Requiring ICD–10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Esomeprazole – Nexium [®] Lansoprazole – Prevacid [®]	Angiodysplasia of Stomach and Duodenum with OR without Mention of Hemorrhage	K31.81*
Omeprazole – Prilosec®	Atrophic Gastritis with Hemorrhage	K29.41
Pantoprazole – Protonix®	Barrett's Esophagus	K22.7*
Rabeprazole – Aciphex®	Chronic Pancreatitis	K86.0, K86.1
	Congenital Tracheoesophageal Fistula	Q39.1, Q39.2
Diagnosis codes submitted on the pharmacy	Cystic Fibrosis	E84.*
claim will bypass the duration of therapy	Eosinophilic Esophagitis	K20.0
limit	Eosinophilic Gastritis	K52.81
	Gastrointestinal Hemorrhage	K92.2
	Gastrointestinal Mucositis (Ulcerative)	K92.81
	Malignant Mast Cell Tumors	C96.2*
	Multiple Endocrine Adenomas	D44.0, D44.2, D44.9
	Tracheoesophageal Fistula	J86.0
	Ulcer of Esophagus with OR without Bleeding	K22.1*
	Zollinger–Ellison Syndrome	E16.4
Bypass Diagnoses Diagnosis code submitted	l on the pharmacy claim will bypass certain limits.	
Albuterol – ProAir HFA®,	Bronchitis, not specified	J40
ProAir [®] Digihaler [™] , ProAir [®] RespiClick [®] ,	Chronic Airway Obstruction	J44.9
Proventil HFA®, Ventolin HFA® YQ	Cystic Fibrosis	E84.*
Levalbuterol – Xopenex HFA® YQ	Emphysema	J43.*
Yearly Quantity Limit (YQ)	Obstructive Chronic Bronchitis, Chronic Obstructive	J44.*
Applies to FFS and All MCOs as of 4/7/21	Asthma	J44.
Anticonvulsants Clonazepam Tablet – Klonopin® BH, QL Clorazepate Tablet – Tranxene–T® BH, QL Diazepam Tablet– Valium® QL Diazepam Oral/Injectable – Valium® BH Lorazepam Injectable – Ativan® BH Carbamazepine – Equetro® BH Behavioral Health Clinical Authorization Required for Children Younger than 6 (BH) Quantity Limits (QL) Applies to FFS and All MCOs as of 11/1/19	Seizures/Convulsions – Bypass BH and/or QL	G40*, P90, R56*
Opioids	Cancer – Bypasses QL, MME	C00.*–C96.*
Quantity Limits (QL)	Palliative Care – Bypasses QL, MME	Z51.5

Louisiana Medicaid – Medications Requiring ICD–10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Maximum Morphine Milligram Equivalent (MME) Limits Applies to FFS and All MCOs as of: 7/10/17 – for Cancer and Palliative Care	Second or Third Degree Burns or Corrosions – Bypasses QL, MME	T20.2*, T20.3*, T20.6*, T20.7*, T21.2*, T21.3*, T21.6*, T21.7*, T22.2*, T22.3*, T22.6*, T22.7*, T23.2*, T23.3*, T23.6*, T23.7*, T24.2*, T24.3*, T24.6*, T24.7*, T25.2*, T25.3*, T25.6*, T25.7*
10/1/18 – for Second or Third Degree Burns 1/1/19 – for Sickle Cell Crisis	Sickle Cell Crisis – Bypasses QL , MME	D57.0*, D57.21*, D57.41*, D57.81*
	Cancer – Bypasses CU, PU	C00.*-C96.*
Opioids	Palliative Care – Bypasses CU, PU	Z51.5
Long-acting Opioid Not Initial Therapy – Requires Previous Opioid Use (PU) Concurrent Use of Opioid and	Second or Third Degree Burns or Corrosions – Bypasses PU	T20.2*, T20.3*, T20.6*, T20.7*, T21.2*, T21.3*, T21.6*, T21.7*, T22.2*, T22.3*, T22.6*, T22.7*, T23.2*, T23.3*, T23.6*, T23.7*, T24.2*, T24.3*, T24.6*, T24.7*, T25.2*, T25.3*, T25.6*, T25.7*
Benzodiazepine Restricted (CU)	Sickle Cell Crisis – Bypasses PU	D57.0*, D57.21*, D57.41*, D57.81*
Applies to FFS and All MCOs as of 10/1/19	Seizures/Convulsions – Bypass CU for Incoming Benzodiazepine, NO Bypass for Incoming Opioid	G40*, P90, R56*
Cefixime – Suprax® Bypasses PA requirement for non-preferred cefixime Applies to FFS and All MCOs as of 1/1/21	Unspecified sexually transmitted disease	A64
Bypass Diagnoses (Continued) Diagnosis	code submitted on the pharmacy claim will bypass certain	n limits.
Dapagliflozin – Farxiga®	Heart Failure (as of 7/1/21)	I50*
Bypass of Prior Use (PU) Requirements Applies to FFS and All MCOs	Chronic Kidney Disease (as of 10/1/21)	N18*
Empagliflozin - Jardiance® Bypass of Prior Use (PU) Requirements Applies to FFS and All MCOs as of 1/1/22	Heart Failure	I50*
Enzyme Replacement Applies to FFS and A	All MCOs as of 1/1/21	
Cerliponase alfa – Brineura TM	Neuronal ceroid lipofuscinosis	E75.4
Eliglustat tartrate – Cerdelga®	Gaucher disease	E75.22
Imiglucerase – Cerezyme®	Gaucher disease	E75.22

Louisiana Medicaid – Medications Requiring ICD–10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Taliglucerase alfa – Elelyso®	Gaucher disease	E75.22
Migalastat − Galafold [™]	Fabry (-Anderson) disease	E75.21
Asfotase alfa – Strensiq®	Perinatal/infantile-onset and juvenile-onset hypophosphatasia	E83.39
Velaglucerase alfa – Vpriv®	Gaucher disease	E75.22
Miglustat – Zavesca®	Gaucher disease	E75.22
Hemophilia Agents Applies to FFS and All	MCOs as of 1/1/21	
Advate® [antihemophilic factor (recombinant)]	Hemophilia A	D66
Adynovate® [antihemophilic factor (recombinant)]	Hemophilia A	D66
Afstyla® [antihemophilic factor (recombinant), single chain]	Hemophilia A	D66
Alphanate® [antihemophilic factor/von	Hemophilia A	D66
Willebrand factor complex (human)]	Von Willebrand disease	D68.0
AlphaNine® SD [coagulation factor IX (human)]	Hemophilia B	D67
Alprolix® [coagulation factor IX (recombinant)]	Hemophilia B	D67
BeneFIX® [factor IX (recombinant)]	Hemophilia B	D67
Coagadex®[coagulation factor X (human)]	Hereditary Factor X deficiency	D68.2
Corifact® [factor XIII concentrate (human)]	Factor XIII deficiency	D68.2

Louisiana Medicaid – Medications Requiring ICD–10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Eloctate® [antihemophilic factor (recombinant)]	Hemophilia A	D66
Esperoct® [antihemophilic factor (recombinant)]	Hemophilia A	D66
Feiba® NF [anti-inhibitor coagulant	Hemophilia A	D66
complex]	Hemophilia B	D67
Hemlibra® [emicizumab-kxwh]	Hemophilia A	D66
Hemofil-M [antihemophilic factor (human)]	Hemophilia A	D66
Humate-P® [antihemophilic factor/von	Hemophilia A	D66
Willebrand factor complex (human)]	Von Willebrand disease	D68.0
Idelvion® [coagulation factor IX (recombinant)]	Hemophilia B	D67
Ixinity® [coagulation factor IX (recombinant)]	Hemophilia B	D67
Jivi® [antihemophilic factor (recombinant)]	Hemophilia A	D66
Koate® DVI [antihemophilic factor (human)]	Hemophilia A	D66
Hemophilia Agents Continued Applies to	FFS and All MCOs as of 1/1/21	
Kogenate® FS [antihemophilic factor (recombinant)]	Hemophilia A	D66
Kovaltry® [antihemophilic factor (recombinant)]	Hemophilia A	D66
Mononine® [coagulation factor IX (human)]	Hemophilia B	D67
Novoeight® [antihemophilic factor (recombinant)]	Hemophilia A	D66
	Hemophilia A	D66
Novesovan® DT (accordation factor VII)	Hemophilia B	D67
Novoseven® RT [coagulation factor VIIa (recombinant)]	Factor VII deficiency	D68.2
(recombinant)	Glanzmann's thrombasthenia	D69.1
	Acquired Hemophilia	D68.311
Nuwiq® [antihemophilic factor (recombinant)]	Hemophilia A	D66
Obizur® [antihemophilic factor (recombinant)]	Hemophilia A	D66
Profilnine® SD [factor IX complex]	Hemophilia B	D67

Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes		
Generic – Brand Examples	Diagnosis Description	ICD-10 Codes
Rebinyn® [coagulation factor IX (recombinant)]	Hemophilia B	D67
Recombinate TM [antihemophilic factor (recombinant)]	Hemophilia A	D66
Rixubis® [coagulation factor IX (recombinant)]	Hemophilia B	D67
Sevenfact® [coagulation factor VIIa	Hemophilia A	D66
(recombinant)-jncw]	Hemophilia B	D67
Tretten® [coagulation factor XIII A-subunit (recombinant)]	Factor XIII A-subunit deficiency	D68.2
Vonvendi® [von Willebrand factor (recombinant)]	Von Willebrand disease	D68.0
Wilate® [von Willebrand factor / coagulation	Hemophilia A	D66
factor VIII complex (human)]	Von Willebrand disease	D68.0
Xyntha® [antihemophilic factor (recombinant)]	Hemophilia A	D66
Xyntha® Solofuse® [antihemophilic factor (recombinant)]	Hemophilia A	D66
Diabetic Testing Supplies Applies to FFS a	and All MCOs as of 1/1/21	
	Gestational Diabetes	O24.4*
	Diabetes in Pregnancy	O24*
Blood Glucose Test Strips and Lancets	Type 1 Diabetes Mellitus	E10*
	Type 2 Diabetes Mellitus	E11*
Quantity is limited based on diagnosis	Other and Unspecified Diabetes Mellitus	E08*, E09*, E13*
	Long-Term (Current) Use of Insulin [Insulin-treated Non-Type 1 Diabetes Mellitus]	Z79.4

Louisiana Medicaid – Medications Requiring ICD-10 Diagnosis Codes

Notes

- * any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD–10–CM diagnosis code
- – any **ONE** number or letter of an assigned ICD–10–CM diagnosis code
- BH one of these diagnoses will bypass the Behavioral Health Clinical Authorization requirement for children younger than 7 years old
- CU one of these diagnoses will bypass the concurrent use restriction
- $\mathbf{MME}-one\ of\ these\ diagnoses\ will\ by pass\ the\ maximum\ Morphine\ Milligram\ Equivalent\ limit$
- $\boldsymbol{P}\boldsymbol{U}-\text{one}$ of these diagnoses will bypass the requirement for previous use of another agent
- QL one of these diagnoses will bypass the quantity limit

From www.lamedicaid.com, follow the Medicaid Programs and Initiatives link to Pharmacy to find all provider notifications regarding Fee–For–Service Pharmacy policies. The posted policies may contain ICD–9–CM diagnosis codes; however, this table may be used to determine applicable ICD–10–CM diagnosis codes for the medications included in these policies.

Other medications may require an ICD-10-CM diagnosis code. All Schedule II narcotics require a diagnosis code. In cases where the monthly prescription limit is exceeded, an ICD-10-CM diagnosis code is required on all prescriptions in excess of the monthly prescription limit.

Revised January April 2022

Page 22 of 23

Page 23 of 23